Interim Estimates of 2025–26 Seasonal Influenza Vaccine Effectiveness — United States, September 2025–February 2026

In the United States, annual influenza vaccination has been recommended for all persons aged ≥6 months, including during the 2025-26 season. Interim influenza vaccine effectiveness (VE) estimates were calculated for patients with acute respiratory illness-associated outpatient visits and hospitalizations from three U.S. respiratory virus VE networks during the 2025-26 influenza season, using a test-negative case-control design. Among children and adolescents aged <18 years, VE was 38%-41% against influenza outpatient visits and 41% against influenza-associated hospitalization. Among adults aged ≥18 years, VE was 22%-34% against influenza outpatient visits and 30% against influenza-associated hospitalization. Among children and adolescents, VE against influenza A ranged from 37% (against outpatient visits) to 42% (against hospitalization) across settings; among adults, VE against influenza A ranged from 30% (against hospitalization) to 34% (against outpatient visits) across settings. Among children and adolescents, VE against influenza A(H3N2)-associated outpatient visits was 35% and against influenza A(H3N2)-associated hospitalization was 38%. VE against influenza B outpatient visits ranged from 45%-71% among children and adolescents and was 63% among adults. Other estimates of VE were not statistically significant or were not reportable. Although interim influenza VE is lower during the 2025-26 influenza season than it was during recent influenza seasons, these findings demonstrate that influenza vaccination still provides protection against influenza. CDC recommends influenza vaccination; U.S. influenza vaccines remain available for persons aged ≥6 months.

Authors

Publication Details

Journal
MMWR Morbidity and Mortality Weekly Report
Published
2026-03-12
DOI
https://doi.org/10.15585/mmwr.mm7509a2
Primary Topic
Influenza Virus Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Interim Estimates of 2025–26 Seasonal Influenza Vaccine Effectiveness — United States, September 2025–February 2026

Elie Saade, Brendan Flannery, Danielle M. Zerr, Ousseny Zerbo et al.
MMWR Morbidity and Mortality Weekly Report
Influenza Virus Research Studies
article

Interim Estimates of 2025–26 Seasonal Influenza Vaccine Effectiveness — United States, September 2025–February 2026

Elie Saade, Brendan Flannery, Danielle M. Zerr, Ousseny Zerbo, Caitlin Ray, Varsha Neelam, Stacey L. House, Sara Y. Tartof, Nicola P. Klein, Malini B. DeSilva, Joanna L. Kramer, Olivia L. Williams, Ayzsa Tannis, Sascha Ellington, Karen J. Wernli, Colin Rogerson, Kiran A. Faryar, Lora Nordstrom, Lisa M. Keong, Christina Albertin, Omobosola Akinsete, Sifang Kathy Zhao, Kristina Wielgosz, Nathaniel M. Lewis, Elizabeth Wettick, Kristin Dascomb, Brianna Wickersham, Tamara Sheffield, Haris M. Ahmad, Brian D. Williamson, Vel Murugan, Leah Odame-Bamfo, Heidi L. Moline, Michelle A. Barron, Jennifer E. Schuster, Jay Krishnan, John K. Williams, Richard K. Zimmerman, Lina S. Sy, Daniel C. Payne, Brian E. Dixon, Mary A. Staat, Laura S. Stewart, Jessie R. Chung, Duck-Hye Yang, Natalie A. B. Bontrager, Aleda M. Leis, Taylor Kristicevich, Sarah W. Ball, Fatimah S. Dawood, Allison L. Naleway, Emily L. Reeves, CDC Influenza Vaccine Effectiveness Collaborators, Megan C. Freeman, David Mayer, Janet A. Englund, Natasha B. Halasa, Marian G. Michaels, Manjusha Gaglani, Amanda McKillop, Ashley M. Price, Mary E. Moffatt, Geoffrey A. Weinberg, James D. Chappell, Leila C. Sahni, Shaun J. Grannis, John Hansen, Vasanthi Avadhanula, Charlene McEvoy, Patrick Maloney, Elizabeth P. Schlaudecker, Shikha Garg, Samantha M. Olson, Krissy Moehling Geffel, Ivana A. Vaughn, Juliana DaSilva, Katherine Adams, Eileen J. Klein, Marie K. Kirby, Carrie Reed, Daniel Bride, Toan C. Ong, Rangaraj Selvarangan, S. Bianca Salas, Stephanie A. Irving, Amanda B. Payne, Emmanuel B. Walter, Tara Curley, Zachary A. Weber, Peter G. Szilagyi, Jennifer DeCuir, Karthik Natarajan, Emily T. Martin, Julie A. Boom
article en

Abstract

In the United States, annual influenza vaccination has been recommended for all persons aged ≥6 months, including during the 2025-26 season. Interim influenza vaccine effectiveness (VE) estimates were calculated for patients with acute respiratory illness-associated outpatient visits and hospitalizations from three U.S. respiratory virus VE networks during the 2025-26 influenza season, using a test-negative case-control design. Among children and adolescents aged <18 years, VE was 38%-41% against influenza outpatient visits and 41% against influenza-associated hospitalization. Among adults aged ≥18 years, VE was 22%-34% against influenza outpatient visits and 30% against influenza-associated hospitalization. Among children and adolescents, VE against influenza A ranged from 37% (against outpatient visits) to 42% (against hospitalization) across settings; among adults, VE against influenza A ranged from 30% (against hospitalization) to 34% (against outpatient visits) across settings. Among children and adolescents, VE against influenza A(H3N2)-associated outpatient visits was 35% and against influenza A(H3N2)-associated hospitalization was 38%. VE against influenza B outpatient visits ranged from 45%-71% among children and adolescents and was 63% among adults. Other estimates of VE were not statistically significant or were not reportable. Although interim influenza VE is lower during the 2025-26 influenza season than it was during recent influenza seasons, these findings demonstrate that influenza vaccination still provides protection against influenza. CDC recommends influenza vaccination; U.S. influenza vaccines remain available for persons aged ≥6 months.

MMWR Morbidity and Mortality Weekly ReportVol. 75(9)
Zero hunger
Openalex Percentile: Top 26%
Influenza Virus Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.